AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 13: TRAINING IN CRITICAL CARE CARDIOLOGY

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Patrick T. O'Gara (Chair)	Brigham and Women's Hospital Cardiovascular Division—Director, Clinical Cardiology; Harvard Medical School—Professor of Medicine	None	None	None	Radiometer*	Lantheus Medical ImagingNIH*	None
Jesse E. Adams, III	Louisville Cardiology Group; Baptist Medical Associates; University of Louisville, Division of Cardiology— Associate Clinical Professor of Medicine	None	None	None	Radiometer*	None	None
Mark H. Drazner	UT Southwestern Medical Center—Professor, Medical Director, Heart Failure, Ventricular Assist Devices, and Cardiac Transplantation; James M. Wooten Chair in Cardiology	None	None	None	None	 American Heart Journal HeartWare† Journal of Cardiac Failure Medtronic* NIH/NHLBI* Thoratec* 	None
Julia H. Indik	University of Arizona— Associate Professor of Medicine	Horizon CME Mayo Clinic	None	None	• NIH	• Boston Scientific†	None
Ajay J. Kirtane	Columbia University Medical Center, New York Presbyterian Hospital—Chief Academic Officer, Center for Interventional Vascular Therapy; Director, Interventional Cardiology Fellowship Program and Catheterization Laboratory Quality	None	None	None	None	 Abbott Abiomed* Boston Scientific* Eli Lilly* Medtronic* St. Jude Medical* Vascular Dynamics* 	None
Kyle W. Klarich	Mayo Clinic—Professor of Medicine	None	None	None	None	None	None
L. Kristin	Duke University Medical	• ACP	None	None	Amylin	 AHA† 	None

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Newby	Center—Professor of Medicine	AstraZeneca BioKier CAMC Health Education & Research Institute CardioDx Cubist/INC Research Daiichi- Sankyo DSI/Lilly Genentech GlaxoSmithKline* JAHA Janssen Pharmaceuticals Johnson & Johnson MedScape/ TheHeart.org Navigant Novartis MetroHealth System Phillips Roche VoxMedia			 Eli Lilly Bristol Myers Squib* David H. Murdock Foundation* GlaxoSmithKline* Google Life Sciences Merck* Duke University* NIH NIH/NHLBI* PCORI* 	AstraZeneca† JAHA Society of Chest Pain Centers	
Benjamin M. Scirica	Brigham and Women's Hospital—Associate Physician	 Arena Pharmaceuticals AstraZeneca BiogenIdec Boston Clinical Research Institute Bristol-Myers Squibb Eisai Forest Pharmaceuticals 	None	None	 AstraZeneca* Bayer * Bristol-Myers Squibb* Daiichi-Sankyo* Eisai* Eli Lilly* Gilead Sciences* GlaxoSmithKline* Johnson & Johnson* 	None	None

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
		 GE Healthcare GlaxoSmithKline Gilead Sciences Lexicon Merck St. Jude Medical 			Merck*Novartis*		
Thoralf M. Sundt, III	Harvard Medical School— Professor of Surgery; Massachusetts General Hospital— Chief, Division of Cardiac Surgery	None	None	None	None	 Chief of Cardiac Surgery† Edwards Thrasos* 	 Defendant, myocardial protection, 2014 Defendant, surgical injury to coronary artery, 2012 Defendant, management of prosthetic endocarditis, 2012 Defendant, traffic accident involving an individual with aortic dissection, 2012

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \geq 5% of the voting stock or share of the business entity, or ownership of \geq \$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

†No financial benefit.

^{*}Significant relationship.

ACP = American College of Physicians; AHA = American Heart Association; JAHA = Journal of the American Heart Association; NHLBI = National Heart, Lung, and Blood Institute; NIH = National Institutes of Health; PCORI = Patient-Centered Outcomes Research Institute.